Tempest Therapeutics (NASDAQ:TPST – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Institutional and Insider Ownership
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Tempest Therapeutics and Profound Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempest Therapeutics | N/A | N/A | -$26.26 million | ($6.01) | -0.22 |
| Profound Medical | $16.10 million | 15.33 | -$42.57 million | ($1.24) | -5.48 |
Tempest Therapeutics has higher earnings, but lower revenue than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Tempest Therapeutics has a beta of -1.85, meaning that its share price is 285% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.
Profitability
This table compares Tempest Therapeutics and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempest Therapeutics | N/A | -355.61% | -121.21% |
| Profound Medical | -206.76% | -78.88% | -64.06% |
Analyst Recommendations
This is a summary of recent recommendations for Tempest Therapeutics and Profound Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempest Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Profound Medical has a consensus price target of $12.00, indicating a potential upside of 76.73%. Given Profound Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Tempest Therapeutics.
Summary
Profound Medical beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.
About Tempest Therapeutics
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
